Faronin tiedote 23 Helmikuuta:
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II BEXMAB trial evaluating bexmarilimab in combination with azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) have been accepted for presentation at the 66th Annual Scientific Meeting of the British Society for Haematology (BSH), taking place 19–21 April 2026 in Liverpool, UK.
Ymmärränkö oikein että posterin erittelee: (presenting author)
Dr Emma Searle The Christie NHS Foundation Trust and the University of Manchester
EIKÄ Faronin henkilöstöä ole ainakaan esillä?
Otsikon mukaista Abstractia kannattaisi alkaa haeskelemaan konsa konferenssi alkaa tänään.